Phase 2 Clinical Trial of KH617

NCT07138001 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Recurrent Glioblastoma

Interventions

COMBINATION_PRODUCT: KH617+TMZ
DRUG: KH617
DRUG: TPC: TMZ or Platinum (cisplatin or carboplatin)+VP-16

Sponsor

Sichuan Honghe Biotechnology Co., Ltd.